Best Life Sciences Companies in Cambridge, United Kingdom

Developer of oral small molecule inhibitors for treating blood cancers. This pharmaceutical entity focuses on creating therapeutic agents that target specific proteins involved in tumor progression. The research involves modulating gene expression by disrupting the interaction of transcription co-activation factors within cancer cells. The primary therapeutic candidate is designed to address multiple myeloma and other hematological malignancies by binding to bromodomains. This approach aims to reduce the production of proteins that drive tumor growth. The development process includes clinical evaluation to assess safety and efficacy across various patient populations.

Funding rounds

• May 2026Series D$220M
• May 2025Series C$120M
• Jul 2024Series C$35M
• Jul 2023Series C$25M

Founders & team

Azim SuraniCo-FounderWill WestCo-Founder & CEO

Investors

Takeda Ventures, Morningside, Nesta Impact Investments, Providence Investment Company, UK Innovation Science & Seed Fund, RA Capital Management

Tech stack

CloudflareCloudflare Browser InsightsCookieyesCore-JsDocusignElementor

Manufacturer of programmed human cells for research and drug discovery. This entity utilizes gene-targeting technology to express transcription factors that reprogram induced pluripotent stem cells into defined human cell types. These products include various nerve, immune, and muscle cell lines designed for use in laboratory assays, disease modeling, and therapeutic development. The technology enables the production of consistent cell models for applications such as CRISPR screening, electrophysiology, and immunocytochemistry.

Funding rounds

• Jan 2026Series C$50M
• Dec 2024Series B$30M
• Dec 2021Series B$37.2M
• Sep 2021Series B$103M

Founders & team

Mark KotterCo-FounderPrzemek OblojChief Executive Officer

Investors

Resilience, Puhua Capital, Charles River Laboratories, Foresite Capital, Arch Venture Partners, Metaplanet

Tech stack

Apple Icloud MailBootstrapCart FunctionalityCloudflareCloudflare Bot ManagementCore-Js

Developer of single-cell functional analysis using a droplet-based platform. The technology uses light rays to precisely control picoliter-scale droplets, enabling scalable assays for drug discovery, therapeutics, and basic research. The system facilitates sequential assays and the real-time dispensing of cells for downstream applications. It supports research into biomolecule secretion, cell-cell communication, and targeted cell killing mechanisms. The platform allows for the precise control of droplet merging to characterize individual cell responses.

Funding rounds

• Apr 2026Series B$27M
• Aug 2023Series B$49M
• Dec 2022Series B$25.1M
• Mar 2022Series A$14.2M

Founders & team

Cameron FraylingFounderPaul LoeffenChief Executive Officer

Investors

M Ventures, Arch Venture Partners, Illumina Ventures, OMX Ventures, ND Capital, Longwall Venture Partners

Developer of therapeutics targeting the deoxyribonucleic acid damage response in cancer. These treatments focus on inhibiting specific enzymes involved in cellular repair mechanisms to induce damage within malignant tissues. The approach utilizes small-molecule inhibitors to disrupt survival pathways in tumor cells. Research efforts concentrate on identifying biological targets that regulate replication stress and genomic stability. These therapeutic candidates are evaluated for use as monotherapies or in combination with other agents to address solid tumors.

Funding rounds

• Nov 2025Series D$115M
• Jul 2021Series C$153M
• Aug 2018Series B$84M
• Sep 2016Series A$36M

Founders & team

Shweta NairFounderElena SeroffArtist. Art Director. Curator. FounderUrs SeeberBusiness Owner

Investors

Andera Partners, Life Sciences Partners, Novartis, Arix Bioscience, SV Health Investors, IP Group

Tech stack

BootstrapCloudflareCloudflare Bot ManagementCookie InformationFont AwesomeGodaddy

Biotechnology company developing next‑generation antibody therapies. The company focuses on creating next-generation antibody therapies. Their lead asset targets ATTR cardiomyopathy, a form of amyloidosis. The antibody is designed to selectively remove established amyloid fibrils.

Funding rounds

• Mar 2026Series A$86.9M

Founders & team

Mihriban TunaChief Executive Officer

Investors

Frazier Life Sciences, F-Prime Capital, Qiming Venture Partners, SR One, Cambridge Enterprise, Cambridge Innovation Capital

Provider of rapid protein expression and screening systems for biotechnology labs. It helps life science researchers rapidly prototype, screen, and optimize protein expression. The system uses cell-free synthesis, digital microfluidics, and automated workflows to deliver reliable protein access in days rather than months, supporting research, characterization, and scale-up in biotech and pharma labs.

Funding rounds

• Dec 2025Series C$12M
• Oct 2024Series C$75M
• Jun 2024Grant (prize money)$1.5M
• Nov 2023Series B—

Founders & team

Michael ChenCo-Founder & CEOGordon McinroyCo-Founder & COO

Investors

Amadeus Capital, Verve Ventures, RT Partners, M&G, E Ink, Future Planet Capital

Tech stack

Apple Icloud MailBeaver BuilderCart FunctionalityCloudflareCloudflare Bot ManagementCookiebot

Developer of collaborative surgical robotic systems. It offers Versius a small and modular surgical robot that enables all hospitals to offer robotic assisted surgery to the patients. It allow surgeons to design robotic techniques and incorporate laparoscopic equipment for certain parts of the treatment.

Funding rounds

• Apr 2025Series D$131.2M
• Apr 2025Conventional Debt$68.8M
• Sep 2023Series D$165M
• Jun 2021Series D$600M

Founders & team

Mark SlackCo-Founder & Chief Medical OfficerLuke HaresCo-Founder & CIOMassimiliano ColellaCEO

Investors

Ally Bridge Group, Railpen, Tencent, Watrium, PFM Health Sciences, GE Healthcare

Tech stack

Amazon CloudfrontAmazon S3Amazon Web ServicesApolloCloudflareCookieyes

Developer of therapeutics for the treatment of cancer and inflammatory diseases. The company has developed therapeutics that interrupt pathological fibroblast-driven immune signaling and influence innate and adaptive immune responses.

Funding rounds

• Mar 2026Series A$40M
• Aug 2024Grant (prize money)$2M
• Aug 2021Seed$34M
• Apr 2021Seed$11M

Founders & team

David TuvesonCo-FounderSoumya RaychaudhuriCo-FounderMark ColesCo-Founder

Investors

Forbion, Google Ventures, SV Health Investors, Johnson & Johnson Innovation, Northpond Ventures, Ukri

Developer of small molecule inhibitors targeting specific disease associated enzymes. These therapeutic candidates focus on the regulation of cellular quality control processes to address neurodegenerative conditions, heart disease, kidney disease, and fibrosis. The research centers on the modulation of protein degradation pathways to influence disease progression.

Funding rounds

• Oct 2025Series D$13.3M
• Jul 2024Grant (prize money)$5.2M
• Mar 2024Series D$32.2M
• Jan 2021Series C$3.7M

Founders & team

Keith MenearCo-FounderAnker LundemoseCEO

Investors

Innovate UK, Imperial Innovations, Woodford Investment Management, Roche, Pfizer Venture Investments, Sofinnova Partners

Developer of non-invasive breath-based diagnostics for cancer and infectious diseases. It offers Breath Biopsy platform for early detection and precision medicine which uses proprietary technology as a microchip that uses Field Asymmetric Ion Mobility Spectrometry (FAIMS) coupled with software to detect desired biomarkers in a patient's exhaled breath. The first application is an early screening of lung and colon cancer.

Funding rounds

• Oct 2025Grant (prize money)$49.1M
• Mar 2025Series E$2.3M
• Jan 2025Series E$27M
• Apr 2024Series D$5M

Founders & team

David AlonsoCo-Founder & COOBilly BoyleCo-Founder & CEO

Investors

Aviva, Gates, Horizons Ventures, Foxconn Electronics, Ventura Capital, Medtekwiz Advisory

Tech stack

AzureCdnjsCloudflareCloudflare Bot ManagementCookiebotCore-Js

Avita Medical develops and distributes products in Regenerative and Respiratory Medicine. The company’s regenerative and tissue-engineered products provide solutions utilizing the patient’s own skin and the regenerative capability of the human body to treat a wide range of wounds, scars and skin defects. The Regenerative group of products uses proprietary technology to create a Regenerative Epithelial Suspension RES™ – an autologous suspension comprised of the cells and wound healing factors necessary to regenerate natural healthy skin. The Regenerative group of products includes ReCell® for the treatment of burns and Maxillo-Facial procedures, ReCell® for plastics/aesthetics and ReCell® for the treatment of lower leg chronic wounds. Additionally, the company commercializes innovative medical technologies for improved medication delivery and adherence in patients suffering from chronic respiratory diseases. Key respiratory products include the Funhaler® incentive asthma spacer designed specifically for the pediatric market. The Breath-A-Tech™ range optimizes the delivery of aerosol medication in the management of Asthma and COPD

Funding rounds

• Aug 2025Post IPO$15M
• Nov 2019Post IPO$82M
• Feb 2019Post IPO$14.4M
• Dec 2018Post IPO$8.9M

Founders & team

Michael PerryCEO

Investors

Hunter Hall, Oceania Capital Partners, DMP Asset Management, BioScience Managers, ATO, Defense.gov

Tech stack

AccessibeAcquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform Launch

Developer of T-cell-based rtherapeutics for cancer treatment. It offers T-cell receptor-based drugs that recognise specific cancers and patient’s own T cells to kill the cancer cells and eradicate the tumour.

Funding rounds

• Nov 2025Series A$32M
• Nov 2023Series A$59.4M

Founders & team

Haydn ProsserCo-Founder & DirectorAllan BradleyCo-Founder & CEO

Investors

Sanofi Ventures, University of Cambridge, Sofinnova Partners, F-Prime Capital, Digitalis Ventures, Cambridge Innovation Capital

Tech stack

Animate.CssAnime.JsExactmetricsFancyboxGodaddyGoogle Analytics